Enasidenib, an IDH2 Inhibitor based on Phase 1 Trial  High-Response rate in patients with IDH2 mutation

Enasidenib, an IDH2 Inhibitor based on Phase 1 Trial High-Response rate in patients with IDH2 mutation

User Photo
hematologydebates

2 years
52 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Amer M Zeidan, MBBS, explains Enasidenib, an IDH2 Inhibitor based on Phase 1 Trial High-Response rate in patients with IDH2 mutation at Imedex Great Debates 2018
Up Next Autoplay
User Photo